CytomX Therapeutics Inc

6C1

Company Profile

  • Business description

    CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

  • Contact

    151 Oyster Point Boulevard
    Suite 400
    South San FranciscoCA94080
    USA

    T: +1 650 515-3185

    E: [email protected]

    https://www.cytomx.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    69

Stocks News & Analysis

stocks

CSL’s latest result suggests the worst may be over

Relief replaces disappointment but can growth return?
stocks

ASX listed pharma boosted by weight loss drugs

GLP-1 momentum drives earnings for narrow moat share.
stocks

Nvidia earns upgrade as AI buildouts accelerate

Demand for AI infrastructure shows no signs of slowing.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,271.406.300.07%
CAC 408,334.5066.68-0.79%
DAX 4026,258.11311.88-1.17%
Dow JONES (US)53,217.39342.60-0.64%
FTSE 10010,824.2631.720.29%
HKSE25,566.9917.80-0.07%
NASDAQ26,293.53108.89-0.41%
Nikkei 22566,311.9393.63-0.14%
NZX 50 Index13,917.30149.121.08%
S&P 5007,674.0237.74-0.49%
S&P/ASX 2009,076.0010.400.11%
SSE Composite Index3,986.3034.120.86%

Market Movers